In short
AML is an aggressive adult leukemia classified by genetics; intensive or lower-intensity therapy is chosen by fitness and risk.
What this guide covers: Overview · Diagnosis · Treatment · Relapsed
Overview
Acute myeloid leukemia (AML) is a fast-growing blood cancer in adults arising from immature myeloid cells. A related subtype, acute promyelocytic leukemia, is treated distinctly. Diagnosis combines blood counts, bone marrow examination, and genetic testing to define the disease.
Diagnosis
And Risk Bone marrow aspirate and biopsy confirm the presence of blasts. Cytogenetic and molecular studies sort patients into favorable, intermediate, and adverse risk groups. This risk assessment, along with age and fitness, shapes the treatment plan. Measurable residual disease testing refines monitoring.
Treatment
Fit patients typically receive intensive induction with cytarabine and an anthracycline. Some receive a targeted antibody based on CD33 status. Patients who are older or less fit may use lower-intensity regimens combining a hypomethylating agent with a targeted drug. Allogeneic transplant is considered for high-risk disease.
Relapsed
Disease Relapse calls for repeat genomic profiling to find actionable changes. Enrollment in clinical trials and, when suitable, stem cell transplant are key considerations.
Sources and further reading
One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.
General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.





